Epocrates vs Micromedex

Micromedex is sold to institutions, quoted per organization with no public price. A hospital pharmacy or toxicology service that licenses it gets Poisindex toxicology, RED BOOK pricing, NeoFax and pediatric content, IV compatibility and, since September 2025, an AI search that returns cited answers. Merative says it validated that search through internal testing, external clinician validation and real-world testing, and publishes no independent accuracy data. It also claims the 2026 Best in KLAS ranking for point-of-care drug reference. A toxicology service gets no matching content from Epocrates, whose epocrates+ page lists none, so Epocrates is out for that buyer. The Epocrates buyer is a resident or attending paying personally, at $24.99 per month or $179.99 per year, with a group plan for teams. In a 2016 count of detected interactions, Epocrates reached 250 of 400 and Micromedex 236, on versions of that year.